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Abstract
Patients suffering from coronary heart disease (CHD) are often affected by mental
health issues, such as depression, anxiety and low quality of life. This affects the pro-
gression of their heart condition negatively. Natriuretic peptides might play a role in
the patients’ mental adaptation to CHD. Studies on A-type natriuretic peptide (ANP)
found an anxiolytic effect of this peptide in humans. B-type natriuretic peptide (BNP)
was also shown to have anxiolytic properties in an animal model but results in humans
were so far inconclusive. To determine the role of BNP with regard to mental health
in CHD patients, data from a large multicenter trial were analyzed. Based on previous
studies it was hypothesized that high levels of BNP would be negatively associated
with the patients’ physical state, but positively with their mental health.
The hypotheses were tested with cross-sectional data of 529 mildly to moderately de-
pressed CHD patients. N-terminal proBNP (NT-proBNP) was assessed at baseline
together with a variety of psychometric tests and somatic data from medical records.
Mental health was assessed repeatedly over 24 months using standardized question-
naires. The association of NT-proBNP and anxiety was subsequently assessed in more
detail using longitudinal data of 308 patients with baseline NT-proBNP measures and
anxiety measures from baseline to 24-months follow-up.
Linear regression models adjusted for sex, age, and physical functioning showed sig-
nificant negative associations of baseline NT-proBNP with depression, anxiety, vital
exhaustion, negative affectivity, and depressive coping but positive associations with
self-rated mental health, despite worse physical functioning. Linear regression models
of the longitudinal data adjusted for sex, age, body mass index, and physical func-
tioning showed that baseline NT-proBNP was a significant predictor for anxiety at
baseline, 1, 6, 12, 18, and 24 months. Surprisingly, a linear mixed model analysis
showed a significant time*NT-proBNP*sex interaction when NT-proBNP as fixed fac-
tor was dichotomized into the lowest vs. the three highest quartiles. In this sample,
women with very low levels of NT-proBNP had persisting high levels of anxiety while
in all other groups anxiety decreased over the investigated period of two years. The re-
sults indicate that (NT-pro)BNP is associated with the patients’ overall mental health
and anxiety over two years. However, different pathways for men and women seem to
be present. These results are discussed, and possible mechanisms are suggested.
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Zusammenfassung
Patienten, die an koronarer Herzkrankheit (KHK) leiden, sind häufiger von psychis-
chen Problemen wie Depression, Angstzuständen und niedriger Lebensqualität betrof-
fen. Dies beeinflusst den Verlauf ihrer Herzerkrankung negativ. Natriuretische Peptide
könnten eine Rolle dabei spielen, wie KHK-Patienten psychisch auf ihre Erkrankung
reagieren. Studien an A-Typ natriuretischem Peptid (ANP) fanden eine anxiolytis-
che Wirkung dieses Peptids beim Menschen. B-Typ natriuretisches Peptid (BNP)
zeigte auch in einem Tiermodell anxiolytische Eigenschaften, Ergebnisse beim Men-
schen waren bisher jedoch nicht eindeutig. Um die Rolle von BNP in der psychischen
Gesundheit von KHK-Patienten zu bestimmen, wurden Daten aus einer großen mul-
tizentrischen Studie analysiert. Vor dem Hintergrund der bestehenden Studienlage
wurde die Hypothese aufgestellt, dass hohe BNP-Werte negativ mit dem körperlichen
Zustand der Patienten, aber positiv mit ihrer psychischen Gesundheit korrelieren.
Die Hypothese wurde mit Querschnittsdaten von 529 leicht bis mittelgradig depressiven
KHK-Patienten getestet. N-terminales proBNP (NT-proBNP) wurde zu Studienbeginn
zusammen mit einer Vielzahl von psychometrischen Test- und somatischen Daten aus
der Krankenakte erhoben. Die psychische Gesundheit der Patienten wurde regelmäßig
über 24 Monate hinweg mit standardisierten Fragebögen untersucht. Im Anschluss
wurde der longitudinale Zusammenhang von NT-proBNP und Angst detaillierter an-
hand von Daten von 308 Patienten mit NT-proBNP Messungen zu Studienbeginn und
Angstmessungen von Studienbeginn (Baseline) bis zum letzten Testzeitpunkt nach 24
Monaten untersucht.
Lineare Regressionsmodelle, adjustiert für Geschlecht, Alter und körperliche Funktions-
fähigkeit, zeigten signifikante negative Zusammenhänge von NT-proBNP mit Depres-
sion, Angst, vitaler Erschöpfung, negativer Affektivität und depressiver Krankheitsbe-
wältigung sowie positive Korrelationen mit selbsteingeschätzter psychischer Gesund-
heit trotz schlechterer körperlicher Funktionsfähigkeit. Lineare Regressionsmodelle
der Längsschnittdaten, adjustiert für Geschlecht, Alter, Body Mass Index und kör-
perliche Funktionsfähigkeit, zeigten, dass die Baseline NT-proBNP Werte ein sig-
nifikanter Prädiktor für Angstwerte der Baseline, 1, 6, 12, 18 und 24 Monaten war.
Überraschenderweise zeigte ein gemischtes lineares Modell eine signifikante Zeit*NT-
proBNP*Geschlecht-Interaktion, wenn NT-proBNP als fester Faktor in das niedrigste
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vs. die drei höchsten Quartile dichotomisiert wurde. In dieser Stichprobe hatten Frauen
mit sehr niedrigen NT-proBNP-Werten anhaltend hohe Angstwerte, während in allen
anderen Gruppen die Angstwerte über den Testzeitraum von zwei Jahren abnahmen.
Die Ergebnisse deuten darauf hin, dass (NT-pro)BNP mit der allgemeinen psychischen
Gesundheit der Patienten und dem Verlauf der Angst über zwei Jahre zusammen-
hängt. Allerdings scheinen unterschiedliche Wirkmechanismen für Männer und Frauen
zu bestehen. Diese Ergebnisse werden diskutiert und mögliche Mechanismen erläutert.
VII
1 Introduction
Since pre-Christian time, the heart has been considered the home of emotions, con-
necting heart and psyche with each other. This is also manifest in everyday language
where the heart is associated with feelings, such as "warm-hearted", "change of heart",
or "heartbroken". With increasing anatomical insight and technical advancements in
medicine the heart was viewed more and more as a mere pump and the heart-psyche-
interaction got limited to the heart receiving signals, e.g. to increase the heart rate in
states of physical or mental stress.
This view began to be challenged with the discovery of the endocrine function of the
heart. Experiments showed that the dilation of the atrium by a balloon and the in-
travenous injection of extracts from atrial myocytes induced diuresis and natriuresis
(Henry et al. 1956; de Bold et al. 1981; de Bold and Salerno 1983). In subsequent years
a polypeptide named atrial natriuretic factor, later atrial natriuretic peptide (ANP),
was isolated and sequenced from rat and human atria.
The first connection to the central nervous system was laid in 1984 when ANP expres-
sion was found in the hypothalamus (Tanaka et al. 1984). Another member of this
peptide family, B-type natriuretic peptide (BNP), was first discovered in porcine brain
and is thus also referred to as brain natriuretic peptide (Sudoh et al. 1988). These
discoveries were a first step towards scientific evidence for a bidirectional interaction
of heart and psyche. Years after the first findings, a possible role of ANP in panic
attacks and an anxiolytic effect of ANP were described in multiple studies (Kellner
et al. 1995; Ströhle et al. 2001; Wiedemann et al. 2001). The anxiolytic function
of ANP is another step towards a biological explanation for the long-thought bidirec-
tional heart-psyche-interaction. While ANP has been studied more extensively, little
is known about the role of BNP in emotion regulation and its effect on anxiety.
In the following, a brief overview of coronary heart disease (CHD) and mental health
issues in CHD patients will be given. Subsequently, natriuretic peptides will be ex-
plained, with a focus on BNP and their role in CHD and recent findings about the
bidirectional association of all three factors, i.e. the role of ANP and BNP with regard
to mental health of CHD patients will be depicted.
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1.1 Coronary heart disease
Acute and chronic ischemic heart diseases are the most common cause of death world-
wide (Robert-Koch-Institut 2015; Nowbar et al. 2019). In Germany approximately
130.000 people die every year from CHD (interchangeably used with coronary artery
disease (CAD)) and its complications such as myocardial infarction and heart failure
(Deutsche Herzstiftung e.V. 2018). CHD can manifest in three stages: 1) silent, 2)
stable, and 3) unstable. While the silent stage is asymptomatic, the second stage
is characterized by stable angina pectoris (AP). Patients often report AP as a tight,
strangling feeling in their chest, or as pain or pressure behind the sternum. However,
discomfort can also be located in the back, arms, or the epigastric region and intensity
varies from sharp pain to only slight discomfort or no pain at all. In stable AP, symp-
toms occur during physical exercise or emotional stress and usually disappear within
five minutes. The third stage includes unstable AP, i.e. symptoms of AP at rest or
sleep, which last longer and can get worse over time. Unstable AP can also lead to ST
elevation myocardial infarction (STEMI) and non-ST elevation myocardial infarction
(NSTEMI).
The pathogenesis of all forms of CHD is the hardening of the coronary arteries, called
atherosclerosis. This inflammatory process is initiated by low density lipoproteins
(LDL), fluctuations of blood pressure, or the effects of tobacco, among other factors,
which injure the walls of the coronary arteries. Inflammation activates macrophages (a
subgroup of immune cells), which produce growth factors and cytokines (e.g. interleukin-
1 (IL-1), interleukin-6 (IL-6), or tumor necrosis factor-alpha (TNF-α)). Cytokines then
induce the proliferation of smooth muscle cells in the coronary arteries, which disturb
the regulation of the width of the blood vessels. Moreover, cytokines facilitate the
development of unstable plaques. These are highly inflammatory accumulations of
cholesterol in the vascular walls, that decrease blood flow to the heart muscle and can
thrombose or embolize when ruptured. The resulting decrease in oxygenation of the
heart muscle can lead to myocardial infarction or sudden cardiac death (Lusis 2000;
Herrmann-Lingen et al. 2014).
The sclerosis and narrowing of the coronary arteries can present in many different ways
and with varying intensity. Cardinal symptoms of CHD are stable and unstable AP
and symptoms often start when the stenosis reaches a critical level around 75%. Of-
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ten symptoms are triggered by physical or mental stress but also arise when a plaque
ruptures, leading to acute coronary syndrome (Herrmann-Lingen et al. 2014).
Due to improved health behaviors (e.g. non-smoking, physical activity, healthy diet)
and improved cardiometabolic risk profiles of patients (blood pressure, glycated hemoglobin
(HbA1c), LDL) as well as improved care of acute myocardial infarction, the incidence
rate and mortality has decreased in Germany. The most recent European Health
Interview Survey (EHIS), conducted in 2014/2015, estimates the overall 12-month-
prevalence of CHD in Germany at 3.7% for women and 6.0% for men. These rates
increase up to 16.0% in women and 24.1% in men 75 years of age and older. The life-
time prevalence of CHD is 6.6% for women and 9.6% for men (Robert-Koch-Institut
2015; Busch and Kuhnert 2017).
1.2 Mental health and coronary heart disease
CHD not only affects the heart and the body, but also the mental state and quality
of life of patients. Anxiety, depression and psychological distress are very common
in CHD patients and influence the course of the disease (Herrmann-Lingen and Buss
2002; Barth et al. 2004; van Melle et al. 2004; Albus et al. 2018). It is likely that
the mental health of CHD patients is also influenced by neurobiological processes that
modulate psychological adaptation.
Cardiac patients have a prevalence of 20-50% for depressive symptoms and up to 29%
for major depressive disorder (Bankier et al. 2004; Albus et al. 2018). Depression
alone, but especially the combination of depression and anxiety, increases the risk of
mortality in CHD (Parissis et al. 2008; Watkins et al. 2013). Even in people without
a diagnosed heart disease depression significantly increases the risk for CHD and my-
ocardial infarction by about 30%, independent of other risk factors (Gan et al. 2014).
This increase in morbidity and mortality in depressed people can be explained by a
combination of multiple factors (Herrmann-Lingen et al. 2014). First, on a physio-
logical level, inflammatory processes can facilitate plaque destabilization, as described
above, and heightened coagulation increases the risk of thrombosis. Moreover, depres-
sion leads to changes in the hormonal stress axis (Wiedemann et al. 2000) and disrupts
the autonomic balance, which is associated with reduced heart rate variability and ar-
rhythmia (Carney and Freedland 2008). Second, depressed CHD patients are less likely
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to adhere to medical advice, including medication, and are less motivated to join reha-
bilitation programs. Third, the decreased energy level during depressive episodes and
the anti-depressive effects of nicotine and overeating often hamper necessary lifestyle
changes, such as smoking cessation, a healthy diet, and physical activity.
Patients often experience the comorbid depression as more burdensome than the so-
matic changes of CHD. Especially patients with maladaptive personality traits such
as type D personality are at high risk of developing a depression. This personality
type is characterized by the combination of negative affectivity and social inhibition
(the inability to communicate emotions in relationships) and has been associated with
increased mortality in CHD patients (Grande et al. 2012). 35-60% of cardiac patients
also commonly describe states of excessive fatigue, decreasing energy and feeling de-
jected or defeated. These symptoms are summarized as vital exhaustion, which is a
strong risk factor for future myocardial infarction, independent of other risk factors
(Appels and Mulder 1988; Kop 1999). The somatic and mental consequences of CHD
collectively reduce the patients’ quality of life, a subjective, multidimensional construct
that can be divided into a physical and a mental domain (Ware and Sherbourne 1992).
In patients with a cardiac disease quality of life is markedly decreased and correlates
more with the subjective New York Heart Association (NYHA) class than with somatic
markers of disease severity, such as left ventricular ejection fraction (LVEF) (Schowal-
ter et al. 2013).
Due to the vital meaning of the heart, cardiac diseases are commonly accompanied by
states of anxiety. This is important and potentially lifesaving as it urges patients to
seek medical help and adhere to health behaviors. This is supported by the finding that
in CHD patients without myocardial infarction or with less severe CHD, anxiety was
found to be a protective factor against mortality and major adverse events (Meyer et al.
2010; Meyer et al. 2015a). However, other studies found contrary results, with anxiety
being an independent risk factor for increased morbidity and mortality (Roest et al.
2010; Watkins et al. 2013), probably by increasing heart rate, blood pressure, and the
increased likelihood of arrhythmia (MacMahon and Lip 2002; Herrmann-Lingen et al.
2014). The physiological effects during states of anxiety (e.g. increased heart rate) can
in turn further increase acute anxiety leading into a vicious circle.
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1.3 Natriuretic peptides
A- and B-type natriuretic peptide are known to counteract the volume overload in
chronic hypertension and heart failure. They lower the blood pressure by inducing
vasodilation and stimulating the excretion of water and sodium and have a wide range
of neuromodulatory effects. BNP is stored with ANP in atrial granules. Moreover, vol-
ume overload stretches the ventricular walls, which increases the transcription of BNP
(Potter et al. 2006; Hodes and Lichtstein 2014). In addition to mechanical stretch
of the myocardium, there are multiple factors that trigger BNP release, including the
sympathetic nervous system, vasopressin, endothelin, and angiotensin II (Luchner and
Schunkert 2004; Meyer and Herrmann-Lingen 2017).
These factors activate the transcription factor GATA-4, which binds to the promoter
of the BNP-encoding gene, which activates the natriuretic peptide B (NPPB)-gene
located on chromosome 1p36.2. Subsequently, the mRNA transcript is expressed as
134 amino acid prepro-BNP. Once secreted, a 26 amino acid sequence is cleaved from
the N-terminus, resulting in proBNP1-108. In a last step, furin (a membranous serine-
protease) cleaves proBNP into the biologically inactive 76 amino acid long N-terminal
proBNP (NT-proBNP) and the active BNP77-108 (Potter et al. 2006; Volpe et al. 2016;
Meyer and Herrmann-Lingen 2017).
Both ANP and BNP bind to the NPR-A receptor which increases the intracellu-
lar cyclic guanosine monophosphate (cGMP) production inducing vasodilation of the
smooth muscle cells and a shift of intraventricular fluid to reduce blood pressure (Sto-
evesandt 2008). Natriuretic peptides are a natural antagonist of the renin-angiotensin-
aldosterone-system (RAAS) and inhibit the release of renin in the kidney. Moreover,
they inhibit the sympathetic nervous system, the release of aldosterone in the adrenal
gland, and the release of vasopressin in the pituitary gland; hormones that increase the
blood volume and thus blood pressure (Luchner and Schunkert 2004; Hodes and Licht-
stein 2014; Volpe et al. 2016). As vasopressin and the sympathetic nervous system
promote the release of natriuretic peptides, this system acts as a humoral feedback-loop
(Inoue et al. 1988).
In addition, natriuretic peptides inhibit the hypothalamic-pituitary-adrenal axis (HPA
axis) in the locus coeruleus, the pituitary gland, the hypothalamus, and the adrenal cor-
tex. The resulting inhibition of norepinephrine (NE), corticotropin-releasing hormone
5
(CRH), cortisol, and adrenocorticotropic hormone (ACTH) counteracts the physio-
logical response to physical and psychological stress (Hodes and Lichtstein 2014). In
addition, natriuretic peptides stimulate vagal afferents, which contribute to internal
stress regulation (Hansson 2002; Yuan and Silberstein 2016). BNP is used more com-
monly as a diagnostic and prognostic marker of cardiac dysfunction than ANP, as it is
mainly released from the ventricles. BNP plasma levels correlate with the severity of
the disease, however for clinical diagnostics and research purposes the levels of the more
stable N-terminal prohormone (NT-proBNP) are used (Ponikowski et al. 2016) since
it does not show severe fluctuations in response to exercise or time of day (Ponikowski
et al. 2016).
1.4 Current state of research on natriuretic peptides and mental
health in coronary heart disease patients
As described above, natriuretic peptides reduce sympathetic tone and affect the ac-
tivity of the HPA axis (Wiedemann et al. 2000; Luchner and Schunkert 2004), thus
antagonizing the neurohumoral activation induced by reduced heart function and the
sympatho-excitatory effects of anxiety. Yet, their role in mental health is still not well
understood. Multiple studies associated ANP with anxiety and showed its anxiolytic-
like function. Early study results revealed an increased secretion of ANP in lactate-
induced panic attacks (Kellner et al. 1995) and an attenuation of symptoms of chole-
cystokinin tetrapeptide (CCK-4)-induced panic in panic disorder patients pretreated
with ANP and healthy participants that exercised for 30 minutes (Ströhle et al. 2001;
Ströhle et al. 2006). Moreover, an independent negative relation of plasma pro-ANP
and anxiety was found in a mixed sample of patients with heart failure and controls
(Herrmann-Lingen et al. 2003), and in alcohol dependence and withdrawal (Koop-
mann et al. 2014; von der Goltz et al. 2014). The association of ANP and anxiety is
especially striking as the emotional and physiological arousal that accompanies states
of anxiety is specifically detrimental for a weakened heart, as in CHD or heart failure
patients.
In contrast to the variety of studies dealing with the role of ANP in CHD, only few
studies addressed the association of BNP with psychosocial factors. Anxiolytic effects
of BNP were first shown in an animal model (Bíró et al. 1996). In patients at risk
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for heart failure or diagnosed with heart failure, no consistent results were found. One
study reported an inverse relation of BNP and anxiety; however, BNP was not an
independent predictor (Meyer et al. 2015c). Other studies found a positive associa-
tion (Tsuchihashi-Makaya et al. 2009) or no association of BNP and self-rated anxiety
(Brouwers et al. 2012). In a sample of 85 CHD patients, no association between anxi-
ety disorder and NT-proBNP was found (Bankier et al. 2009).
Studies on BNP and depression point towards a positive association (Bunevicius et al.
2006; Politi et al. 2007; Brouwers et al. 2014). However, these studies used different
patient populations, including patients with major depressive disorder, brain tumor,
and heart failure. Results on other measures of mental health are scarce. Studies found
a positive association of ANP with vital exhaustion (Herrmann-Lingen et al. 2003),
no association of BNP with type D personality (Pelle et al. 2010), and a negative
association of BNP with quality of life (Laederach-Hofmann et al. 2007).
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2 Research question
The cardiovascular system is complexly involved in the interaction of heart and psy-
che. The heart not only receives psychobiological signals, e.g. via the sympathetic
nervous system, the vagus nerve, and stress hormones, but is also an endocrine organ
itself. Natriuretic peptides relieve the heart by decreasing its pre- and afterload, but
studies also point towards an anxiolytic effect. A replication of these findings would
support an adaptive model of heart-psyche-interaction, which contributes to psycho-
logical adaptation in cardiac disease. The goal of the present work is to explore the role
of (NT-pro)BNP with regard to the mental health of mildly to moderately depressed
CHD patients.
The relationship between CHD and psychosocial state seems to be reciprocal. CHD
limits the physical functioning of patients and thereby decreases their quality of life.
Moreover, depression and anxiety, as common comorbidities of CHD, further impact
the patients’ quality of life negatively. Depression, anxiety, and low quality of life in
turn increase the risk for future adverse cardiac events and worsen the cardiac progno-
sis. Natriuretic peptides seem to play an important role in counteracting this vicious
circle on a physiological as well as psychological level. Therefore, the goal of the pre-
sented secondary analyses is to shed more light onto the relationship of (NT-pro)BNP
with the psychosocial status in CHD patients to broaden the understanding of this
natriuretic peptide and its role in emotion regulation.
In line with the hypothesis that (NT-pro)BNP has a positive effect on the psycho-
logical well-being of CHD patients, a negative association of anxiety, depression and
vital exhaustion with NT-proBNP is expected. As NT-proBNP is a marker of illness
severity, higher levels of NT-proBNP are expected to correlate negatively with patients’
physical quality of life, but positively with patients’ psychological quality of life. With
better well-being and higher psychological quality of life, patients with high levels of
NT-proBNP are expected to show more functional coping with their illness. Based on
previous findings with ANP, baseline BNP is expected to be associated with a decline
of anxiety over time.
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3 Methods
To test the proposed hypotheses, NT-proBNP was entered in a cross-sectional model
as predictor of anxiety, depression, quality of life, vital exhaustion, coping with illness,
and social inhibition and negative affectivity, i.e. type D personality. Subsequently, the
longitudinal association of anxiety and NT-proBNP was assessed in more depth with
baseline NT-proBNP samples and six anxiety measures. Measurements were taken at
baseline and after 1, 6, 12, 18, and 24 months.
3.1 Study design
The data used to assess the assumed association of NT-proBNP with measures of
mental health stem from a multicenter randomized controlled study, the Stepwise Psy-
chotherapy Intervention for Reducing Risk in Coronary Artery Disease (SPIRR-CAD)
trial. Patients (N=570) had clinical evidence of CHD (coronary stenosis > 50% in
recent angiogram or history of percutaneous intervention) and a least mildly elevated
depression scores (Hospital Anxiety and Depression Scale (HADS), Zigmond and Snaith
1983; Herrmann-Lingen et al. 2011). The cut-off on the HADS depression subscale was
set to > 7, to include all possible cases and have a low proportion of false negatives, as
recommended by Zigmond and Snaith (1983). To test whether stepped psychotherapy
is more effective in reducing depressive symptoms, patients were randomized to usual
care plus one information session or usual care plus a stepwise individual and group
psychotherapy intervention (see Appendix for Consort flow chart). Details on the de-
sign of the study have been published in Albus et al. 2011. The primary results of the
SPIRR-CAD trial have been reported in Herrmann-Lingen et al. 2016. The trial pro-
tocol was approved by the ethics committees of all participating centers and the trial
was conducted in accordance with the Helsinki declaration and Good Clinical Practice.
All patients gave written informed consent before being included in the study.
3.2 Assessments
To test the association of NT-proBNP and mental health measures, baseline (N=529)
and 24-months follow-up (N=308) data of patients with valid NT-proBNP samples
at baseline were used. At baseline, blood was drawn from a cubital vein in rest-
9
ing patients and immediately centrifuged. Until analysis at a central lab, the blood
samples were stored at - 80◦C. Serum concentrations were measured using an electro-
chemiluminescence immunoassay, using two monoclonal antibodies (Elecsys, Roche
Diagnostics GmbH, Mannheim, Germany; Prontera et al. 2005).
As the SPIRR-CAD trial took place in Germany, all materials were provided in Ger-
man. Socio-demographic information on age, sex, marital status, highest educational
level, and the patients’ current employment situation was included. The patients’
medical status was taken from their medical records. Anxiety was measured using the
anxiety subscale of the German version of the HADS (Herrmann-Lingen et al. 2011).
Depression scores from the HADS depression subscale were not used for the main anal-
yses as this scale was used as an inclusion criterion and baseline scores are therefore
severely skewed. Instead, the 9-item Patient Health Questionnaire (PHQ) was ana-
lyzed (Spitzer et al. 1999; Löwe et al. 2002). To assess different dimension of coping
with illness the 5-dimensional Freiburg Questionnaire of Coping with Illness (FQCI)
was used (Muthny 1989). Vital exhaustion was measured using the 21-item Maastricht
Questionnaire (MQ) (Appels et al. 1987). The two dimensions of type D personality,
i.e. social inhibition and negative affectivity were assessed with the 14-item Type D
Scale (DS-14) (Denollet 2005). Different dimensions of quality of life were assessed with
the Medical Outcomes Short Form Health Survey (SF-36), including the z-standardized
mental health and physical health component scores (Ware and Sherbourne 1992).
3.3 Data analysis
The association of NT-proBNP with all psychosocial variables was analyzed at baseline
as well as longitudinally from baseline to the 24-month follow up. In both analyses,
descriptives were calculated for the socio-demographic questions. All raw data of the
questionnaires and NT-proBNP levels were tested for normality using a Kolmogorov-
Smirnov test of normality. The test showed severe skewness for NT-proBNP levels
(Figure 1), thus data were log-transformed to approximate a normal distribution (Fig-
ure 2).
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Figure 1: Frequency distribution of NT-proBNP measures at baseline.
Figure 2: Frequency distribution of log-transformed NT-proBNP measures at baseline.
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The association of NT-proBNP levels with illness severity and psychosocial function-
ing was assessed with bivariate Pearson’s correlation analysis or Spearman’s rho, where
applicable. The independent associations of NT-proBNP with the psychometric scales
were assessed with separate linear regression models. To adjust for additional factors,
the regression models were adjusted for sex and additional confounding factors that
were significantly associated with NT-proBNP and the psychometric scale in the cor-
relation analysis.
Longitudinal associations of NT-proBNP and anxiety were analyzed in more depth
using multilevel linear mixed models with the six anxiety measures as level-1 variable,
nested within participants as level-2 variable. Model A included random intercepts for
participants, NT-proBNP as continuous variable, and sex, randomization arm, time,
and the interactions with time as fixed effects. Model B included NT-proBNP as
dichotomized variable comparing the lowest quartile versus the highest three quar-
tiles. Subgroup analysis was done using Student’s t-test for continuous measures and
χ2 analysis for categorical measures. Non-parametric data were compared using Mann-
Whitney-U and Wilcoxon signed-rank tests. All data were analyzed using SPSS (Ver-
sion 24 and 25, IBM Corp., Armonk, NY, USA) and R (Version 3.5.1.).
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4 Summary of the main findings
The cross-sectional analysis in publication 1 (Fangauf et al. 2018) showed that 75% of
the patients scored above the clinically relevant cut-off of 7 on the anxiety subscale of
the HADS. A significant positive association was found between log-transformed NT-
proBNP measures and age, Charlson comorbidity index and the bodily pain subscale
of the SF-36. This scale is scored inversely with higher scores indicating less pain.
Log-transformed NT-proBNP measures showed significant negative associations with
BMI, ejection fraction, and the physical functioning subscale of the SF-36. Results of
the associations with mental health measures confirmed the expected negative asso-
ciation of NT-proBNP with anxiety, depression, negative affectivity, vital exhaustion,
and depressive coping. Positive correlations were found with trust in physicians (a
subscale of the Freiburg Questionnaire of Coping with Illness) and the mental health
subscale of the SF-36. These analyses confirmed the hypothesis that NT-proBNP is
consistently negatively correlated with physical health, but positively correlated with
psychological quality of life. Separate linear regression models for these significant
psychometric scales were constructed and adjusted for sex, age, and physical function-
ing. All models showed significant independent associations of log(NT-proBNP) and
all tested psychometric scales. These results support the hypothesis that in coronary
patients BNP is associated with better mental health, despite the physical limitations
due to the cardiac disease.
The longitudinal analysis in publication 2 (Fangauf et al. 2019) broadens the results of
the first publication on NT-proBNP and anxiety. At 24-months follow-up, 49% of the
patients still scored above the clinically relevant cut-off of 7 on the anxiety subscale
of the HADS, however the anxiety score decreased significantly from baseline to 24-
months in both men and women. The results show a consistent negative association of
baseline NT-proBNP with anxiety measures over the 24 months, independent of age,
sex, BMI, and self-reported physical functioning. NT-proBNP could thus potentially
be prognostically relevant not only for morbidity and mortality, but also for the men-
tal state of cardiac patients. While the results confirm the hypothesis that baseline
NT-proBNP would be associated with a decline of anxiety over 24 months, model A
of the multilevel linear mixed model analysis showed no significant interaction of time
with any of the tested factors. Model B, however, revealed a significant interaction
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of time with NT-proBNP and, surprisingly, a significant sex-effect, showing that in
women with very low levels of NT-proBNP anxiety did not decrease significantly over
the time tested as it did in the rest of the sample. The persisting high levels of anxiety
of this subgroup might be the result of an insufficient up-regulation of BNP despite
the weakened state of their heart due to CHD.
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A B S T R A C T
Natriuretic peptides (NP) are involved in the regulation of blood pressure and blood volume, and are elevated in
patients with coronary artery disease (CAD). They are used as markers for illness severity, but their role in
mental health is not well understood. Recently, A-type NP (ANP) has been associated with reduced anxiety in
studies on cardiac patients; however, this study is the ﬁrst to assess this eﬀect for B-type NP (BNP) and for further
dimensions of well-being and mental health. Depression, anxiety, and distress are more common in CAD patients
than in the general population and are most likely not only inﬂuenced by psychological adaptation but also by
neurobiological processes. We used baseline N-terminal proBNP (NT-proBNP) samples and psychometric as-
sessments of 529 at least mildly depressed (Hospital Anxiety and Depression Scale, depression score ≥ 8) CAD
patients from the multicenter Stepwise Psychotherapy Intervention for Reducing Risk in Coronary Artery Disease
(SPIRR-CAD) trial. Psychosocial status was assessed using standardized self-rating questionnaires on anxiety,
depression, coping with illness, vital exhaustion, type D personality, and quality of life. Separate linear re-
gression models for each psychometric scale revealed signiﬁcant negative correlations of NT-proBNP with an-
xiety, depression, vital exhaustion, depressive coping, and negative aﬀectivity. Moreover, patients with higher
levels of NT-proBNP experienced less bodily pain and had a better self-rated mental health, despite worse
physical functioning. Linear regression adjusted for age, sex, and physical functioning (Short Form Health
Survey [SF-36]) revealed NT-proBNP to be a signiﬁcant predictor for all tested measures of the patients’ psy-
chosocial status. These results indicate that NT-proBNP is not only positively associated with greater disease
severity in mildly to moderately depressed CAD patients but also with better psychosocial status and mental
well-being. Possible mechanisms of this eﬀect are discussed.
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1. Introduction
Considering that coronary artery disease (CAD) is one of the most
common sources of disability and mortality worldwide (Franco et al.,
2011) and that depression and anxiety increase the morbidity and
mortality in patients with CAD, surprisingly little is known about the
neurobiological factors inﬂuencing patients’ mental health and quality
of life. This is considerable since depression as well as anxiety and
psychological distress are common in CAD patients with a prevalence of
20–50% for depressive symptoms, up to 29% for major depressive
disorder, and approximately 45% for anxiety disorders (Bankier et al.,
2004; Herrmann-Lingen and Buss, 2002; Ladwig et al., 2014; Todaro
et al., 2007). Anxiety is regarded as an independent risk factor for in-
creased morbidity and mortality in CAD and post-myocardial infarction
(MI), probably caused by increases in heart rate and in frequency of
arrhythmias (MacMahon and Lip, 2002; Roest et al., 2010; Watkins
et al., 2013). However, other studies found contrary results with an-
xiety acting as a protective factor with regard to mortality and major
adverse events in healthy persons or CAD patients without a history of
MI, attributed to an increase in help-seeking and health behavior in
anxious patients (Meyer et al., 2015a, 2010; Mykletun et al., 2007).
Depression alone, but especially in comorbidity with anxiety, in-
creases the risk of mortality in patients with CAD (Lichtman et al.,
2014). Similar to depression in symptomology is vital exhaustion, a
state of excessive fatigue, decreased energy, and the feeling of being
dejected or defeated. Vital exhaustion is highly prevalent in cardiac
patients (35–60%), and it predicts future MI independently of other risk
factors (Appels and Mulder, 1988; Kop, 1999).
Cardiac patients typically have elevated levels of A- and B-type
natriuretic peptides (ANP and BNP, respectively). ANP and BNP are
secreted by the cardiac atria and ventricles when they are stretched,
such as in patients with heart failure or CAD (Kim et al., 2006). They
induce natriuresis and diuresis leading to a decrease of blood pressure
and of pre- and afterload of the heart. Plasma levels of BNP correlate
with the severity of the cardiac disease. They are synthesized in the
cardiac myocytes as preprohormones and cleaved into proANP/
proBNP. These prohormones are then cleaved in equal parts into the
biologically inactive N-terminal and the active ANP/BNP. Due to longer
half-lives of the N-terminal peptides (NT-proANP/NT-proBNP), their
concentrations are commonly measured for clinical diagnostics and
research purposes (McMurray et al., 2012). Both ANP and BNP bind to
the NPR-A receptor, which is expressed in kidney and heart tissue but
also in the brain, e.g., brain stem nuclei (Abdelalim et al., 2006).
Interestingly, research found that natriuretic peptides seem to be
associated with emotion regulation and attenuate the activity of the
hypothalamic-pituitary-adrenal (HPA) axis (Wiedemann et al., 2000).
They also reduce sympathetic tone, thus counteracting the neurohu-
moral activation typically seen in heart failure (Luchner and Schunkert,
2004). The association of natriuretic peptides and emotion regulation is
compelling as the emotional and physiological arousal that accom-
panies states of anxiety and stress may be especially detrimental for
patients with ischemic cardiomyopathy.
Most research on natriuretic peptides and emotion examined the
relationship of ANP and anxiety, showing that lactate-induced panic
attacks are accompanied by an increased secretion of ANP (Kellner
et al., 1995), whereas pretreatment with ANP attenuated symptoms in
cholecystokinin tetrapeptide (CCK-4)-induced panic (Ströhle et al.,
2001). Moreover, plasma proANP showed an independent negative
correlation with anxiety (Herrmann-Lingen et al., 2003). Apart from
studies regarding anxiety, research on the relation of natriuretic pep-
tides and other aspects of psychosocial functioning is sparse. Data are
contradictory on whether ANP and BNP are related to depression
(Brouwers et al., 2014; Herrmann-Lingen et al., 2003; Murberg et al.,
1997; Pelle et al., 2010). However, vital exhaustion was positively as-
sociated with NT-proANP in one study (Herrmann-Lingen et al., 2003).
Similarly, distress also has a negative inﬂuence on cardiac diseases.
Patients with type D personality, a combination of experiencing nega-
tive emotions and an inhibition to engage in social contact, are espe-
cially vulnerable to the eﬀects of distress (Denollet and Conraads,
2011). Numerous studies reported type D personality to be a determi-
nant for impaired health status, higher rates of rehospitalization and
mortality in patients with chronic heart failure (Denollet and Brutsaert,
1998; Schiﬀer et al., 2010). Also, it may act as a prognostic risk factor in
patients with CAD (Grande et al., 2012). However, other studies found
no eﬀect on adverse outcomes (Coyne et al., 2011; Meyer et al., 2014)
or associations with BNP (Pelle et al., 2010).
Interestingly, the reduced quality of life in cardiac patients corre-
lates more closely with subjective markers of disease severity (e.g., New
York Heart Association (NYHA) class) and emotional status compared
to objective cardiac markers (e.g., left ventricular ejection fraction
(LVEF), BNP) (Ladwig et al., 2014). In contrast to the multiple studies
on proANP, so far only one observational study has assessed the asso-
ciation of NT-proBNP with anxiety. An inverse association was found in
patients with cardiovascular risk factors which failed to reach sig-
niﬁcance as an independent predictor when adjusted for age, sex, body
mass index (BMI), and Framingham score (Meyer et al., 2015b).
In the present study, we examined the relationship of NT-proBNP
and psychosocial status in mildly depressed patients with CAD to
broaden our understanding of this natriuretic peptide and its associa-
tion with emotions. We tested the hypothesis that BNP (as reﬂected by
its proxy NT-proBNP) is a relevant biological factor related to mental
health in CAD patients. In particular, we hypothesized that NT-proBNP
would be negatively correlated with anxiety, depression, vital exhaus-
tion, type D personality, non-functional coping, and physical quality of
life, but positively correlated with functional coping strategies and
psychological quality of life.
2. Methods
2.1. Study design
In a secondary analysis, we used data from the Stepwise
Psychotherapy Intervention for Reducing Risk in Coronary Artery
Disease (SPIRR-CAD) trial, a randomized controlled trial comparing
usual care plus a stepwise psychotherapy intervention to usual care plus
one individual information session. The design and main results have
been described in more detail elsewhere (Albus et al., 2011; Herrmann-
Lingen et al., 2016). The trial was conducted at ten diﬀerent study sites
in Germany in accordance with Good Clinical Practice and the Helsinki
Declaration. All ethics committees of the participating centers approved
the trial protocol and all patients gave their written informed consent.
2.2. Participants
The study enrolled 570 patients aged 18–75 with CAD (coronary
stenosis> 50% as determined by a recent coronary angiogram or his-
tory of percutaneous coronary intervention) and a depression score≥ 8
on the Hospital Anxiety and Depression Scale (HADS) (Zigmond and
Snaith, 1983). Exclusion criteria were severe heart failure (LVEF <
20% or NYHA class IV), severe depressive episodes according to the
Structured Clinical Interview for DSM-IV (SCID) (Wittchen et al., 1997),
other severe or life-threatening physical or mental diseases, and in-
suﬃcient ability to speak German. Data from 529 patients (93%) with
valid baseline NT-proBNP and HADS measurements were included in
the present analysis.
2.3. Assessments
At baseline, all centers assessed the patients’ medical history and
their socio-demographic data (e.g., age, gender, marital status, and
highest educational level) from their medical records and standardized
clinical interviews. The patients’ psychosocial status was assessed using
S.V. Fangauf et al. Psychoneuroendocrinology 96 (2018) 188–194
189
the German versions of standardized self-rating questionnaires.
To assess anxiety symptoms, we used the HADS (Herrmann-Lingen
et al., 2011; Zigmond and Snaith, 1983), a questionnaire with two 7-
item subscales with clinically relevant cut-oﬀ scores of eight points each
(range 0–21).
We used the 9-item depression scale of the Patient Health
Questionnaire (PHQ-9) (Löwe et al., 2002; Spitzer et al., 1999) to assess
depressive symptoms. Each item assesses one of the nine DSM-IV cri-
teria for major depression and scores range from 0 to 27. Scores higher
than ten indicate a moderate level of depression.
The Freiburg Questionnaire of Coping with Illness (FQCI) (Muthny,
1989) was used to examine the patients’ coping styles with their illness
on ﬁve scales, namely depressive coping, active problem-oriented
coping, distracting and encouraging oneself, religiosity and quest for
meaning, and minimization and wishful thinking. All items are rated on
a scale ranging from 1 = “not at all” to 5 = “very much”, and a sum
score is calculated for each subscale. Two additional items assess trust
in physicians.
The 21-item Maastricht Questionnaire (MQ) (Appels et al., 1987)
assesses vital exhaustion. Symptoms of feeling exhausted, dejected, and
defeated are rated ranging from 0 = “not present” to 2 = “present”
with a cut-oﬀ point of> 19 (range 0–42) signifying vital exhaustion.
To measure the two components of type D personality, namely so-
cial inhibition and negative aﬀectivity, we used the 14-item type D
scale (DS-14) (Denollet, 2005) with seven items on each subscale. The
negative aﬀectivity subscale covers feelings of irritability, dysphoria,
and worry, while the social inhibition subscale asks for a lack of social
conﬁdence, discomfort in social interactions, and reticence. Answers
range from 0 to 4 with a cut-oﬀ for the presence of type D≥ 10 on each
of the two scales (range 0–28).
The Medical Outcomes Short Form Health Survey (SF-36) (Ware and
Sherbourne, 1992) assesses physical and mental health-related quality
of life with higher scores signifying better quality of life. This ques-
tionnaire has eight subscales (general mental health, role limitations
because of emotional problems, social functioning, role limitations
because of physical problems, bodily pain, vitality, general health
perceptions, and physical functioning). The mental and physical quality
of life subscales can be summarized as z-standardized mental health
component and physical health component scores, respectively.
Blood was drawn from a cubital vein in resting patients, centrifuged,
aliquoted, and stored at -80 °C until being analyzed. A central core lab
measured serum concentrations of NT-proBNP using an electro-
chemiluminescence immunoassay on a Cobas 8000 or Cobas e411
(Elecsys, Roche Diagnostics GmbH, Mannheim, Germany) using two
monoclonal antibodies (Prontera et al., 2004).
2.4. Data analysis
All raw data from the questionnaires and NT-proBNP measurements
were tested for normality revealing that NT-proBNP levels were se-
verely skewed. To reduce the skewness and approach normal distribu-
tion, data were log-transformed. We calculated bivariate Pearson’s
correlation coeﬃcients (and Spearman’s rho where applicable) between
log(NT-proBNP) and baseline parameters (age, BMI) and markers of
illness severity (NYHA class, LVEF, Charlson comorbidity index (CCI)).
We calculated additional bivariate correlations for log(NT-proBNP)
with each questionnaire and subscale. To examine independent asso-
ciations of NT-proBNP with the patients’ psychosocial and subjective
health status, separate linear regression models were constructed for
each psychometric scale that correlated signiﬁcantly (p< .05) with log
(NT-proBNP). We adjusted the regression analyses for sex and those
possibly confounding factors that showed signiﬁcant associations with
log(NT-proBNP) and the psychometric scales in the bivariate analysis.
All data were analyzed using SPSS (Version 24, IBM Corp., Armonk, NY,
USA).
3. Results
3.1. Baseline characteristics and correlation analysis
Patients in our study had a mean age of 59.3 years, were pre-
dominately male (78.8%), 53.9% were non-working, and most (79.9%)
had a low or medium socioeconomic status (Table 1). Study partici-
pants had a median NHYA class of II and a median of two comorbid-
ities. 87.9% (465 patients) took beta-blockers.
Most of the patients had elevated anxiety scores with 75% scoring
above the clinically relevant cut-oﬀ (≥ 8, HADS anxiety subscale).
59.4% of the patients met the criteria for type D personality.
The median NT-proBNP concentration was 188.2 ng/l (Table 1).
There were signiﬁcant associations of log(NT-proBNP) with age,
Charlson comorbidity index, ejection fraction, and self-reported phy-
sical functioning (all p<0.01), and with BMI, bodily pain (Fig. 1), but
not with beta-blocker medication (rs= .085, p= .052) or NYHA class
(rs= .065, p= .142). We found signiﬁcant negative correlations of log
(NT-proBNP) with most measures of distress, signifying better mental
health scores in patients with higher NT-proBNP concentrations
(Fig. 2).
3.2. Multiple regression analysis
Separate multiple linear regression models were constructed for
each signiﬁcant psychometric scale of the correlation analysis to predict
the patients’ psychosocial status from their NT-proBNP level. The re-
gression models were adjusted for age, sex, and physical functioning
(subscale of SF-36) since these factors showed signiﬁcant correlations
with all psychometric scales. Beta-blocker medication, CCI, NYHA class,
and BMI did not correlate signiﬁcantly (all p-values> .05), therefore
Table 1
Baseline Characteristics.
N/valid N %
Male sex 417/529 78.8
Married 331/502 62.6
Socioeconomic status
Low 217/529 41.0
Medium 206/529 38.9
High 106/529 20.0
NYHA class
I 184/507 34.8
II 237/507 44.8
III 86/507 16.3
Beta-blocker medication 465/529 87.9
M SD
Age, y (N=529) 59.3 9.4
LVEF (N=308) 56.7 14.4
BMI (N=515) 28.4 4.8
CCI (N=529) 2.1 1.4
NT-proBNP, median (IQR), ng/l (N=529) 188.2 382.6
HADS anxiety (N=529) 10.4 3.8
PHQ depression (N=501) 9.9 5.4
DS-14 negative aﬀectivity (N=314) 15.77 4.8
DS-14 social inhibition (N=314) 11.74 5.5
MQ vital exhaustion (N=499) 25.5 10.6
SF-36 physical component summary (N=456) 37.7 9.9
SF-36 mental component summary (N=456) 38.0 11.2
FQCI depressive coping (N=480) 11.9 3.8
FQCI trust in physicians (N=483) 3.6 1.0
FQCI religiosity and quest for meaning (N=484) 12.81 3.6
BMI= body mass index (kg/m²), CCI=Charlson comorbidity index, DS-14 =
fourteen item Type D scale, FQCI= Freiburg Questionnaire of Coping with
Illness, HADS = Hospital Anxiety and Depression Scale, IQR= interquartile
range, LVEF= left ventricular ejection fraction, MQ=Maastricht Vital
Exhaustion Questionnaire, NT-proBNP=N-terminal pro-B-type natriuretic
peptide, NYHA=New York Heart Association, PHQ=Patient Health
Questionnaire, SF-36= Short Form Health Survey.
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they were not included in the regression models. LVEF showed weak
but signiﬁcant correlations with vital exhaustion (r= .131, p= .025),
bodily pain (r = -.123, p= .037), and negative aﬀectivity (r= .189,
p= .001) but not with anxiety, depression, coping or other subscales of
quality of life (all p-values> .05).
All models revealed log(NT-proBNP) to be signiﬁcantly associated
with all tested measures of the patients’ psychosocial status (p< .05,
Table 2), except for trust in physicians which was not signiﬁcant. For
anxiety and vital exhaustion, all factors (log(NT-proBNP), age, sex, and
physical functioning) were signiﬁcant predictors, while for depression,
depressive coping, and mental health all factors except sex were sig-
niﬁcant predictors. For negative aﬀectivity and bodily pain, only log
(NT-proBNP) and physical functioning were signiﬁcant predictors.
Since previous studies had also adjusted for BMI, we performed an
additional analysis including BMI as a predictor, which did not change
the previous results.
In a sensitivity analysis, we also included LVEF as predictor for
those psychometric variables with which it was signiﬁcantly associated
in bivariate analyses, i.e., vital exhaustion, negative aﬀectivity, and the
pain subscale of the SF-36. Although the sample size for these analyses
was substantially reduced (n=308) due to incomplete availability of
LVEF data, the association between (absence of) pain and log(NT-
proBNP) remained signiﬁcant (beta= 0.179, p=0.002). In contrast,
the associations of log(NT-proBNP) with vital exhaustion (beta=
-0.079) and negative aﬀectivity (beta= -0.075) were reduced and lost
statistical signiﬁcance, although the direction of the associations re-
mained unchanged.
Fig. 1. Pearson’s correlation coeﬃcients of log(NT-proBNP) with
medical status and self-rated physical health [* p < .05, **
p < .01, *** p < .001, + higher score= less pain, BMI= body
mass index (kg/m²), CCI=Charlson comorbidity index,
LVEF= left ventricular ejection fraction, SF-36= Short Form
Health Survey].
Fig. 2. Pearson’s correlation coeﬃcients of log(NT-proBNP) with
psychological status and self-rated mental health [* p < .05, **
p < .01, *** p < .001, DS-14= 14-item Type D scale,
FQCI= Freiburg Questionnaire of Coping with Illness, HADS =
Hospital Anxiety and Depression Scale, MQ=Maastricht Vital
Exhaustion Questionnaire, PHQ=Patient Health Questionnaire,
SF-36= Short Form Health Survey].
Table 2
Multiple regression models. Predictor: log(NT-proBNP) adjusted for age, sex
and physical functioning (SF-36).
Dependent variable B Std. Error β p
HADS anxiety −.865 .282 −.135 .002
PHQ-9 depression −.811 .367 −.087 .028
FQCI depressive coping −.723 .296 −.110 .015
MQ vital exhaustion −2.599 .716 −.141 .000
DS-14 negative aﬀectivity −1.027 .381 −.123 .007
SF-36 mental health 3.416 1.375 .105 .013
SF-36 bodily pain 8.183 1.765 .179 .000
DS-14 = fourteen item Type D scale, HADS = Hospital Anxiety and Depression
Scale, MQ=Maastricht Vital Exhaustion Questionnaire, NT-proBNP=N-
terminal pro-B-type natriuretic peptide, PHQ=Patient Health Questionnaire,
SF-36= Short Form Health Survey.
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4. Discussion
In this secondary analysis from a large multicenter trial, we con-
ﬁrmed that NT-proBNP levels in patients with CAD and at least mild
depressive symptoms are associated with markers of their medical and
psychosocial health status. As hypothesized, NT-proBNP showed sig-
niﬁcant inverse correlations with anxiety which persisted after multi-
variate adjustment. Although counterintuitive from a cardiological
perspective, these ﬁndings are biologically plausible and in line with
previous research (e.g., Meyer and Herrmann-Lingen, 2017).
While natriuretic peptides indicate more severe heart disease and
represent powerful and independent prognostic indicators for CAD
events among subjects with stable CAD (Bibbins-Domingo et al., 2007),
they are not causally involved in heart disease but rather understood as
one element of adaptive counter-regulation. By stimulating excretion of
water and sodium they reduce the hemodynamic load on the heart
(Hodes and Lichtstein, 2014). In addition, they may stimulate vagal
aﬀerents (Hansson, 2002) which are known to contribute to internal
stress regulation, an eﬀect that is being used in therapeutic vagus nerve
stimulation (Yuan and Silberstein, 2016). Natriuretic peptides reduce
sympathetic tone (Luchner and Schunkert, 2004) and activity of the
renin angiotensin aldosterone system (RAAS; Hodes and Lichtstein,
2014), thereby partly antagonizing the neuroendocrine activation ty-
pically found in heart failure.
An anxiolytic-like eﬀect of ANP and BNP has been shown in animal
models (e.g., Bíró et al., 1996; von der Goltz et al., 2014). This eﬀect
may be mediated by reduced corticotropin-releasing hormone (CRH)
secretion in limbic structures (Hodes and Lichtstein, 2014; Wiedemann
et al., 2000), which also reduces pituitary and adreno-cortical hormone
secretion and sympathetic tone. Several studies of human probands and
patients with panic disorder or alcohol withdrawal (Koopmann et al.,
2014; Ströhle et al., 2006, 2001) show that exogenous ANP application
or exercise-induced increases in ANP levels reduce clinical symptoms of
anxiety or CCK-4-induced panic attacks. In two previous studies, we
also found inverse associations of pro-ANP with anxiety in cardiac pa-
tient samples (Herrmann-Lingen et al., 2003; Meyer et al., 2015b).
Biologically, it appears plausible and would make sense for natriuretic
peptides to buﬀer against anxious arousal in situations of more severe
heart disease.
While most previous studies on associations of natriuretic peptides
and anxiety mainly looked at (pro)ANP, a link between NT-proBNP and
anxiety has been reported in two publications. In a study by Bankier
and colleagues (2009), interview-diagnosed anxiety disorders and NT-
proBNP showed no signiﬁcant association in a relatively small sample
of 85 CAD patients. In contrast, Meyer and coworkers (2015b) found a
weak negative correlation between NT-proBNP and self-rated symp-
toms of (generalized) anxiety in patients with cardiovascular risk fac-
tors including some patients with CAD or heart failure. However, that
association was no longer signiﬁcant after adjustment for confounders.
Our study is therefore the ﬁrst one showing an independent inverse
association of NT-proBNP with anxiety.
The more surprising ﬁnding in the present study is that NT-proBNP
was also independently associated with lower levels of depression,
negative aﬀectivity, depressive coping, vital exhaustion, bodily pain,
and higher levels of self-rated mental health. At the same time NT-
proBNP indicated more severe physical illness and reduced physical
quality of life which could be expected to rather impair emotional well-
being and mental quality of life. However, associations between mor-
phological or humoral measures of cardiac disease severity usually
show only weak and sometimes no associations with mental well-being.
For example, Juenger et al. (2002) showed that chronic heart failure
patients in general had severely reduced quality of life, but within the
heart failure sample, systolic left ventricular function was unrelated to
any of the dimensions of quality of life measured by the SF-36. Another
study showed that also diastolic dysfunction was unrelated to depres-
sion and mental quality of life in patients with cardiovascular risk
factors (Edelmann et al., 2011). In that study, NT-proBNP was even
unrelated to physical quality of life in adjusted analyses. The negative
association of NT-proBNP with measures of distress beyond anxiety –
despite the presence of more severe physical illness – may suggest not
only an anxiolytic but a more general stress-buﬀering eﬀect of na-
triuretic peptides which has already been described for patients with
alcohol withdrawal (Koopmann et al., 2014).
Associations between natriuretic peptide levels and depressive
symptoms or vital exhaustion have been reported in a few previous
studies and results were inconclusive: Murberg et al. (1997) found a
negative but insigniﬁcant association of pro-ANP and depressive
symptoms on the Zung depression scale in 119 patients with heart
failure. A positive association of pro-ANP with depression and vital
exhaustion was observed in patients with congestive heart failure and
healthy controls (Herrmann-Lingen et al., 2003). However, this asso-
ciation may have mainly been driven by the diﬀerence in both de-
pressive symptoms/vital exhaustion and pro-ANP between healthy
probands and heart failure patients which may have obscured a rela-
tively weak depression-buﬀering eﬀect of BNP per se.
Bunevicius et al. (2017) found a positive association between NT-
proBNP and depressive symptoms (rho=0.240, p=0.026) in patients
awaiting surgery for brain tumors. However, the source and mode of
action of BNP in those patients remained unclear, as most cases of
elevated NT-proBNP occurred in patients without heart disease and NT-
proBNP levels signiﬁcantly diﬀered across diﬀerent tumor entities.
Previous results on the eﬀects of natriuretic peptides in the brain point
towards peripheral BNP usually becoming active in the brain as no BNP
mRNA was detected in the brain (Langub et al., 1995), but BNP was
found in the human cerebral cortex (McKenzie et al., 1994) and the
hypothalamus of monkeys (Abdelalim et al., 2006). BNP might have a
neuroprotective function as it was found to increase cerebral blood ﬂow
and reduce inﬂammation in studies on mice (Hodes and Lichtstein,
2014). By this mechanism, it could have a beneﬁcial eﬀect in brain
disease, although that eﬀect may be too weak to compensate for phy-
sical and emotional sequelae of brain tumors.
4.1. Limitations
While there are some reasons to believe that the association be-
tween NT-proBNP and mental health could be causal in a way that BNP
improves well-being, the cross-sectional design of our study does not
allow us to draw such causal conclusion. It is also conceivable that
psychosocial stress in turn reduces the release of BNP.
Although this study was conducted on a fairly large sample, it has to
be noted that the majority of our study participants were male white
Germans with CAD, at least mild symptoms of depression, and ac-
companying elevations in other dimensions of distress. Thus, the results
might not be readily generalizable to women or other races and eth-
nicities, to non-depressed CAD patients, nor those with other physical
illnesses such as brain diseases, or healthy subjects.
Previous studies showed that the incidence and possibly also the
pathophysiology of CAD diﬀer between men and women (Wakabayashi,
2017). However, our ﬁndings were stable when adjusting for sex in the
multivariate analyses. For gender-speciﬁc analyses, future studies need
to recruit more equally and our results also need replication in patients
with other illnesses or from other racial/ethnic backgrounds.
Symptoms of anxiety and depression were only assessed by self-re-
port. Interview-based diagnoses of anxiety disorders or depressive
episodes might yield diﬀerent results. Finally, longitudinal observations
and experimental designs such as those used for ANP will be important
for identifying the causal mechanisms behind the observed associations.
4.2. Conclusion
Our results suggest that BNP, like ANP, may have anxiolytic-like
properties. Furthermore, this is the ﬁrst study to show that (NT-pro)
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BNP is associated with well-being and better mental health of CAD
patients in multiple dimensions, including depression, coping with ill-
ness, and quality of life. The results point towards a more general stress-
buﬀering function of BNP ultimately shielding the heart not only from
ﬂuid overload but also from excessive neuroendocrine activation, and
possibly from psychosocial distress increasing such activation.
Experimental and longitudinal studies are needed to further assess the
psychoprotective function of this natriuretic peptide.
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A B S T R A C T
Objective: Patients with coronary heart disease (CHD) suﬀer from physical limitations, but also from psycho-
logical distress. Natriuretic peptides may be involved in the neurobiological processes that modulate psycho-
logical adaptation, as they are increased in heart disease and seem to have an anxiolytic-like function.
Longitudinal data on this association are scarce.
Methods: To assess the relationship between NT-proBNP and anxiety (Hospital Anxiety and Depression Scale
(HADS)), we used secondary data from a multicenter trial from baseline to 24months. Patients (N=308, 80.8%
male, mean age 60.1 years) had stable CHD and moderate levels of depression (HADS ≥8).
Results: Multiple linear regression adjusted for age, sex, BMI, and physical functioning revealed NT-proBNP as a
signiﬁcant predictor for anxiety at baseline, 1, 6, 12, 18, and 24months (all p < .05). Linear mixed model
analysis with the six anxiety measures as level-1 variable and NT-proBNP as ﬁxed factor revealed a signiﬁcant
time*NT-proBNP interaction (t(1535.99)=−2.669, p= .01) as well as a signiﬁcant time*NT-proBNP*sex in-
teraction (t(1535.99)= 3.277, p= .001), when NT-proBNP was dichotomized into lowest vs. the three highest
quartiles.
Conclusion: Our results indicate a stable negative association of baseline NT-proBNP with anxiety over two years.
In men and women, diﬀerent pathways modulating this relationship appear to be in eﬀect. Female patients with
very low NT-proBNP levels, despite their cardiac disease, show persistently higher levels of anxiety compared to
women with higher levels of NT-proBNP and compared to men.
Trial name: A Stepwise Psychotherapy Intervention for Reducing Risk in Coronary Artery Disease (SPIRR-
https://doi.org/10.1016/j.jpsychores.2019.05.006
Received 18 December 2018; Received in revised form 15 May 2019; Accepted 19 May 2019
⁎ Corresponding author at: University of Göttingen Medical Center, Department of Psychosomatic Medicine and Psychotherapy, Von-Siebold-Str. 5, 37075
Göttingen, Germany.
E-mail addresses: stella.fangauf@med.uni-goettingen.de (S.V. Fangauf), thomas.meyer@med.uni-goettingen.de (T. Meyer),
christian.albus@uk-koeln.de (C. Albus), lutz.binder@med.uni-goettingen.de (L. Binder), deter@charite.de (H.-C. Deter),
ladwig@helmholtz-muenchen.de (K.-H. Ladwig), michal@uni-mainz.de (M. Michal), joram.ronel@barmelweid.ch (J. Ronel), arothen@gwdg.de (A. Rothenberger),
wolfgang.soellner@klinikum-nuernberg.de (W. Söllner), wachter@med.uni-goettingen.de (R. Wachter), cora.weber@oberhavel-kliniken.de (C.S. Weber),
cherrma@gwdg.de (C. Herrmann-Lingen).
1 See acknowledgement for other members of the study group.
Journal of Psychosomatic Research 123 (2019) 109728
0022-3999/ © 2019 Elsevier Inc. All rights reserved.
T
CAD).
Trial registration:www.clinicaltrials.govNCT00705965; www.isrctn.com ISRCTN76240576.
1. Introduction
Patients with coronary heart disease (CHD) have an increased pre-
valence of psychological distress and mental disorders. It was reported
that 20–50% of CHD patients show symptoms of depression and
20–30% fulﬁll the criteria for major depression [1–3]. Since mental
diseases, in particular depression, worsen the progression and prognosis
of CHD, it is important to diagnose and treat these comorbidities ap-
propriately. Studies reported that CHD patients with comorbid de-
pression show higher numbers of complications and have a 1.6–2.5-fold
increased risk of recurrent coronary events and all-cause death [1,4].
While depression is an established cardiac risk factor [5], the impact of
anxiety is less clear, as there is conﬂicting evidence, whether anxiety
increases or reduces the risk of mortality. In multiple studies anxiety
was found to be independently associated with an increased risk of
mortality in healthy individuals and CHD patients, while others re-
ported no such association [6]. In a study by Meyer and colleagues,
higher anxiety scores were associated with reduced mortality in 4864
patients undergoing an exercise test, including both CHD patients
without myocardial infarction (MI) and patients without CHD [7].
The role of anxiety in cardiac disease may be confounded by the
neurohumoral eﬀects of natriuretic peptides. These peptides are typi-
cally elevated in heart failure and not only induce natriuresis, diuresis
and vasodilation, but also attenuate the activity of the hypothalamic-
pituitary-adrenal (HPA) axis and reduce sympathetic tone [8,9]. They
might thus be regarded as antagonists to the sympatho-exitatory eﬀect
of anxiety. A-type natriuretic peptide (ANP) was found to exert anxio-
lytic eﬀects in rodents and humans and has been negatively associated
with anxiety in both cardiac patients and patients with alcohol with-
drawal [10–14]. While the eﬀect of ANP on anxiety has been assessed in
multiple studies, only few studies concerned the relationship between
B-type natriuretic peptide (BNP) and psychological measures, even
though BNP and its N-terminal prohormone (NT-proBNP) are fre-
quently used as markers of illness severity and prognosis in patients
with heart failure. Recent studies also suggest a role of BNP in emotion
regulation, however these ﬁndings are inconsistent, and longitudinal
data are scarce.
In a recently published cross-sectional analysis, we found a link
between high serum concentrations of NT-proBNP and lower levels of
anxiety, depression and further measures of mental health [15]. Pa-
tients with higher levels of NT-proBNP had a better overall mental
health status, despite their somatic symptoms and worse physical
functioning. To further assess the signiﬁcance of NT-proBNP in the
emotion regulation of CHD patients, we aimed at analyzing the long-
itudinal association of NT-proBNP and anxiety.
2. Methods
2.1. Study design
This is a post-hoc analysis of data from the Stepwise Psychotherapy
Intervention for Reducing Risk in Coronary Artery Disease (SPIRR-CAD)
trial to assess the longitudinal association of baseline NT-proBNP with
anxiety. SPIRR-CAD, a randomized controlled trial, comparing usual
care plus one individual information session to usual care plus a step-
wise psychotherapy intervention, was conducted in ten tertiary care
centers in Germany. The design of the study, recruitment path and main
results are described in more detail elsewhere [16,17]. Brieﬂy, the
study tested whether a stepwise psychotherapy intervention added to
usual care improves depressive symptoms more than a single
information session. Primary endpoint was the change in depressive
symptoms (Hospital Anxiety and Depression Scale (HADS)) from
baseline to 18months. The results showed that depressive symptoms
decreased signiﬁcantly in both groups with no signiﬁcant diﬀerence
between the groups or sexes. There was, however, a signiﬁcant inter-
action with type D personality, i.e. patients with type D personality
showed greater improvements in the stepwise psychotherapy group
than in the usual care plus one information session group. The SPIRR-
CAD trial further assessed multiple secondary endpoints, including
additional biomarkers (high sensitivity C-reactive protein, cortisol, in-
terleukin 10, CD-40 L, ﬁbrinogen, creatinine, and thyroid-stimulating
hormone). As these were not the focus of the present post-hoc analysis,
they were not analyzed. All ethics committees of the study sites ap-
proved the trial protocol and the study was conducted in accordance
with the Helsinki Declaration and Good Clinical Practice. All patients
gave written informed consent before enrollment. The present analysis
used data at all time points of the SPIRR-CAD trial i.e., baseline (T0),
1 month (T1), 6 months (T2), 12months (T2b), 18months (T3) and
24months (T4).
2.2. Participants
The main study enrolled 570 patients, 308 (54%) of whom had valid
baseline NT-proBNP measures and HADS-anxiety measures at all six
time points. Patients were eligible to participate when showing angio-
graphic (coronary stenosis > 50%, as determined by a recent coronary
angiogram) or clinical (history of percutaneous coronary intervention)
evidence of CHD and a depression score≥ 8 on the HADS-depression
subscale. Inclusion in the study further required suﬃcient knowledge of
the German language, and patients had to be free of symptoms of severe
heart failure (left ventricular ejection fraction (LVEF) < 20% or New
York Heart Association (NYHA) class IV) or other life-threatening
mental or physical diseases at baseline. Due to ethical concerns, pa-
tients with severe depressive episodes (according to Structured Clinical
Interview for DSM-IV (SCID)) had to be excluded from the study.
Included patients were between 18 and 75 years of age.
2.3. Assessments
The patients' medical history, medication and sociodemographic
data were collected from medical records and standardized interviews.
Anxiety was assessed using the German version of the HADS ques-
tionnaire. This commonly used screening instrument has 14 items to
assess symptoms of depression and anxiety in non-psychiatric hospita-
lized patients with seven items on each subscale [18,19]. It was de-
veloped to exclude symptoms that might equally arise from mental or
somatic disease, such as fatigue. The scale shows good internal con-
sistency and has been validated in numerous studies in CHD patients.
According to the original publication, a cut-oﬀ of≥8 should be used for
each subscale to include all possible cases and have a low proportion of
false negatives. A cut-oﬀ of≥11 should be used to only include cases of
high symptomatology, thereby reducing the possibility of a mis-
classiﬁcation of false positive cases [19].
To measure NT-proBNP levels, blood was drawn from a cubital vein
in resting patients at baseline. The patients' blood was immediately
centrifuged and stored at−80 °C until analyzation at a central lab using
an electro-chemiluminescence immunoassay (Elecsys, Roche
Diagnostics GmbH, Mannheim, Germany). NT-proBNP is commonly
used for research purposes and clinical diagnostics due to its longer
half-live and higher stability as compared to BNP. Given that the
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precursor pro-BNP is hydrolytically cleaved in an equal stoichiometric
ratio into the active BNP molecule and its biologically inactive N-
terminal fragment, the NT-proBNP analyte can be used as a valid proxy
for serum BNP concentration.
2.4. Data analysis
All raw data were tested for normality and log-transformed to ap-
proach normal distribution if they were severely skewed, such as la-
boratory measures of NT-proBNP. Pearson's correlations were calcu-
lated to characterize the sample in terms of sociodemographic data. To
control for confounding factors, multiple regression models with base-
line NT-proBNP as independent and anxiety as dependent variables
were calculated adjusting for sex, age, body-mass index (BMI), and
physical functioning, as determined from the corresponding subscale of
the SF-36 questionnaire (Medical Outcomes Short Form Health Survey;
20). To assess the longitudinal association of NT-proBNP and anxiety,
multilevel linear mixed models were calculated. The models included
the six assessments of anxiety as level-1 variable, nested within parti-
cipants as level-2 variable. In model A, we included random intercepts
for participants, as well as NT-proBNP as continuous measure, sex,
randomization arm, time, and the interactions with time as ﬁxed ef-
fects. In model B, we entered the same factors into the model, however
we dichotomized NT-proBNP into lowest vs. highest three quartiles.
Diﬀerences between subgroups (e.g., sexes, quartiles of NT-proBNP)
were assessed using χ2 analysis for categorical measures and Student's t-
test for continuous measures. For comparisons of non-parametric data,
Mann-Whitney-U and Wilcoxon signed-rank tests were performed. All
data were analyzed using SPSS (Version 25, IBM Corp., Armonk, NY,
USA) and R (Version 3.5.1.).
3. Results
3.1. Baseline characteristics
The mean age of the sample was 60.1 (SD=8.9) years. The majority
of patients were male (80.8%), non-working (53.9%), and married
(75.0%) and most patients had a medium or low socioeconomic status
(Table 1). Patients had a mean HADS-depression score of 10.2, but the
majority did not have a major depressive disorder (MDD) according to
SCID (68.2%). The mean anxiety score on the HADS-anxiety subscale
was 10.2 (SD=3.7) at baseline and 76.9% had clinically relevant
scores ≥8. After 24months, approximately half of the patients (49%)
still had elevated anxiety scores, whereas the mean score had dropped
to 7.7 (SD=4.2). Separate analysis by sex showed that the prevalence
of anxiety at baseline was 74.3% for men and 88.1% for women, which
decreased to 47.4% and 55.9%, respectively, after 24months. This re-
duction in the HADS-anxiety scores was signiﬁcant in both male (t
(248)= 9.91, p < .001) and female study participants (t(58)= 6.34,
p < .001).
Comparison of the included versus the excluded sample revealed
that included patients were signiﬁcantly older (mean (SD)=60.1 (8.9)
versus 58.0 (10.1)), had lower levels of NT-proBNP
(median=165.5 ng/l versus 261.3 ng/l) and higher LVEF (mean
(SD)=58.8 (13.8) versus 53.7 (14.6)). Moreover, they had a higher
socioeconomic status (22.7% versus 15.1%) and a signiﬁcantly higher
percentage was married (75.0% versus 54.5%). The samples did not
diﬀer on baseline anxiety or other descriptive variables.
Comparison of patients with versus without MDD showed sig-
niﬁcantly diﬀerent levels of NT-proBNP (F(3, 304)= 3.35, p= .02).
Patients without MDD displayed higher NT-proBNP levels (median
(IQR)= 188.55 (318.15)) than patients with mild or moderate MDD
(median(IQR)=123.9 (196.80) vs. 113.25 (203.33)). Patients in par-
tial remission (N=7) were not included in this analysis due to their
small number.
3.2. Correlation analysis
Correlation analysis revealed signiﬁcant negative associations be-
tween baseline log(NT-proBNP) and HADS-anxiety measures at all time
points (Table 2). The associations remained signiﬁcant at all time points
in a multiple regression analysis adjusted for age, sex, BMI, and physical
functioning (subscale of the SF-36 questionnaire) (all p < .05).
3.3. Multilevel linear mixed model
The results of model A (continuous measure of NT-proBNP) revealed
no signiﬁcant interaction of any of the factors with time (all p > .05).
In model B (lowest vs. three highest quartiles of NT-proBNP), we found
a signiﬁcant time*NT-proBNP interaction (t(1535.99)=−2.669,
p= .01), as well as a signiﬁcant time*NT-proBNP*sex interaction (t
(1535.99)= 3.277, p= .001). Fig. 1 and 2 show the diﬀerent time
course of anxiety for patients in the lowest versus the three highest
quartiles of NT-proBNP, separately for the two genders. The mean va-
lues illustrate the signiﬁcantly diﬀerent course of anxiety in women
with NT-proBNP levels< 86 ng/l versus ≥86 ng/l (Fig. 1), and the si-
milar course in men with low versus high NT-proBNP (Fig. 2).
3.4. Sex-speciﬁc analysis
To further explore the unexpected sex diﬀerence that was found in
model B, we performed an exploratory analysis to compare NT-proBNP
levels of men and women at baseline. Overall, the median level of NT-
proBNP did not diﬀer signiﬁcantly between men and women
(U=7118.5, Z=−0.396, p= .71). Comparing the male (N=249)
and female (N=59) sample, χ2 analysis and Student's t-test showed a
Table 1
Baseline characteristics.
N/ valid N %
Male sex 249/308 80.8
Married 225/300 75.0
Socioeconomic status
low 113/308 36.7
medium 125/308 40.6
high 70/308 22.7
SCID major depression
none 210/308 68.2
mild 39/308 12.7
moderate 52/308 16.9
Partial remission 7/308 2.3
NYHA class
I 114/298 38.3
II 137/298 46.0
III 47/298 15.8
Beta-blocker medication 265/308 86.0
M SD
Age, y (N=308) 60.1 8.9
LVEF (N=176) 58.8 13.8
BMI (N=303) 28.7 4.8
CCI (N=308) 2.0 1.5
T0 NT-proBNP, median (IQR), ng/l (N=308) 165.5 277.1
T0 HADS depression (N=308) 10.2 2.5
T0 HADS anxiety (N=308) 10.2 3.7
T1 HADS anxiety (N=308) 9.2 4.1
T2 HADS anxiety (N=308) 8.4 4.0
T2b HADS anxiety (N=308) 8.4 4.1
T3 HADS anxiety (N=308) 7.7 4.0
T4 HADS anxiety (N=308) 7.7 4.2
BMI= body-mass index (kg/m2), CCI=Charlson comorbidity index,
HADS=Hospital Anxiety and Depression Scale, IQR= interquartile range,
LVEF= left ventricular ejection fraction, NT-proBNP=N-terminal pro-B-type
natriuretic peptide, NYHA=New York Heart Association, SCID=Structured
Clinical Interview for DSM-IV.
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signiﬁcant diﬀerence in NYHA class (χ2= 6.79, p= .03) and LVEF (t
(174)=−2.27, p= .03), with women having both a higher LVEF and a
higher NYHA class. Men and women did not diﬀer in age, BMI, and
Charlson comorbidity index. As the sample of women was relatively
small, more extensive analyses were not possible.
4. Discussion
In the present secondary analysis of the SPIRR-CAD trial, we in-
vestigated the longitudinal association of anxiety and NT-proBNP in
mildly to moderately depressed coronary artery disease patients. The
Table 2
Correlation analysis.
HADS-anxiety measure Baseline 1month 6months 12months 18months 24months
log(NT-proBNP) Pearson correlation −0.198 −0.159 −0.151 −0.223 −0.129 −0.152
p-value (2-tailed) 0.000 0.005 0.008 0.000 0.024 0.007
Fig. 1. Mean scores of HADS anxiety over 24months in women with the lowest versus the 3 highest quartiles of baseline NT-proBNP. HADS=Hospital Anxiety and
Depression Scale, NT-proBNP=N-terminal pro-B-type natriuretic peptide.
Fig. 2. Mean scores of HADS anxiety over 24months for low and high baseline NT-proBNP in men. HADS=Hospital Anxiety and Depression Scale, NT-proBNP=N-
terminal pro-B-type natriuretic peptide.
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results indicate that higher baseline levels of NT-proBNP were asso-
ciated with persistently lower levels of HADS-anxiety scores over
24months. To our knowledge, this is the ﬁrst study with such a large
sample and a follow-up of two years. Our results extend the ﬁndings of
previous studies on natriuretic peptides and anxiety showing an inverse
relationship [10,12,15,21], however, they are in contrast to studies in
patients with heart failure that found positive or no associations of (NT-
pro)BNP and HADS anxiety [22,23]. As these studies were conducted in
a diﬀerent patient population and either cross-sectional, or had a short
follow-up period, they are not readily comparable to our ﬁndings.
Brouwers and colleagues used anxiety as a predictor for the course of
NT-proBNP over 9months. In 94 heart failure patients they found no
signiﬁcant inﬂuence of baseline anxiety levels on the course of BNP.
This supports our hypothesis that BNP aﬀects the course of anxiety.
Even though the present results do not prove causality, they support
this notion. We hypothesize that an insuﬃcient up-regulation of BNP,
despite cardiac disease, results in more enduring anxiety than in pa-
tients with higher levels of this natriuretic peptide.
The results of linear mixed model A did not conﬁrm a linear asso-
ciation between baseline NT-proBNP and anxiety over time and did not
render a signiﬁcant interaction eﬀect. Model B, with dichotomized NT-
proBNP values, detected a signiﬁcant time*NT-proBNP and time*NT-
proBNP*sex interaction term. The results show a signiﬁcantly diﬀerent
course of anxiety for women with very low versus higher levels of NT-
proBNP. While women with higher levels of NT-proBNP had a con-
tinuous decrease in anxiety over 24months, women with very low le-
vels of NT-proBNP did not exhibit such change and remained at a high
level of anxiety over the entire course of the study, irrespective of their
treatment assignment. Male patients with very low levels of NT-proBNP
also exhibited higher levels of anxiety; however the course of anxiety
over 24months did not diﬀer from that observed in men with higher
levels of NT-proBNP. These results point towards a non-linear associa-
tion between NT-proBNP and anxiety with higher levels of anxiety, if
the body is unable to up-regulate NT-proBNP despite a cardiac disease.
While the negative association between NT-proBNP and anxiety is
in line with previous literature, the interaction with the patients' sex
was unexpected. The results cannot be explained by the patients' age,
BMI, comorbidity, or medication as these parameters did not diﬀer
between men and women. Further research with a more balanced re-
presentation of both sexes is needed to elaborate why this eﬀect was
only present in women.
Previous studies described sex diﬀerences in NT-proBNP levels,
psychological conditions and cardiac disease separately, but the inter-
action of these factors has not been studied. Overall, female CHD pa-
tients seem to have a high prevalence of depression and anxiety (as
women in epidemiological and other clinical samples). However, few
studies present data separated by sex, and, in addition, women are still
underrepresented in most studies on cardiac diseases. A recent sys-
tematic review concluded that women experience more depressive
symptoms than men shortly after a cardiac event as well as long-
itudinally [24]. Moreover, women have naturally higher levels of BNP
than men, possibly mediated by circulating free testosterone [25,26].
However, we found no signiﬁcant diﬀerence in NT-proBNP levels for
women compared to men. This might be due to 71% of women in our
sample being post-menopausal, a state associated with decreasing levels
of NT-proBNP [25,27]. Even though NT-proBNP is an established
marker of disease severity in heart failure and other cardiac illnesses,
the multitude of factors that inﬂuence its level (including age, sex
steroids, and BMI) call its prognostic value as an isolated predictor into
question and warrants further sex-speciﬁc interventions.
4.1. Limitations
As the present results are a secondary analysis of the SPIRR-CAD
trial, in which NT-proBNP and anxiety were not primary endpoints and
patients had moderate to high levels of depression, a study with a less
pre-selected sample of heart patients would be more suitable. While the
present results stem from a large multicenter trial, they have to be in-
terpreted under the consideration that the number of women in this
sample was small, with the majority being male white Germans. The
results are thus not readily generalizable to female cardiac patients or
other races and ethnicities. Moreover, the inclusion criteria demanded
stable CHD and a HADS-depression score≥ 8, thus we cannot assess the
additional eﬀects of the cardiac disease and the depressive symptoms
on the association of anxiety and NT-proBNP. Additionally, many pa-
tients also had elevations in other dimensions of distress. The results
thus cannot be generalized to patients with other somatic or mental
illnesses or healthy subjects. Due to the nature of our data, we cannot
attribute the course of anxiety to changes in NT-proBNP. As 46% of the
sample did not have valid measures for all 6 time points and had to be
excluded for the present analysis, there is the possibility of a selection
bias. Selected patients had higher ejection fraction and thus also lower
levels of NT-proBNP, however with a long follow-up of two years it is
common that mostly less severely ill patients have valid measures for all
time points.
4.2. Conclusion
Our results show a stable negative association of baseline NT-
proBNP and anxiety over two years. However, diﬀerent pathways in
men and women appear to modulate this relationship. Especially
women who were not able to up-regulate their BNP at baseline despite
their cardiac disease, exhibit persistently higher levels of anxiety,
compared to women with higher levels of BNP and compared to men. In
contrast, baseline anxiety did not predict the change in anxiety, arguing
for a probable causal eﬀect of BNP on anxiety rather than vice versa.
However, measuring NT-proBNP levels at multiple time points (in
parallel to anxiety scores) and using cross-lagged-model statistics could
help clarify this issue. Nevertheless, our results suggest an anxiolytic-
like function of BNP, acting as a humoral feedback signal shielding the
diseased heart from the adverse eﬀects of overshooting anxiety.
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6 General discussion
Cardiovascular morbidity and emotional distress have been pathologically linked by a
large body of epidemiological evidence. However, most studies focused on the role of
depression in pathways linking the regulation of cardiovascular homeostasis and stress,
while the impact of anxiety has often not been taken into account. As natriuretic
peptides are present both in the vascular system and the brain, they are of particular
interest in this respect since they exert peripheral vasoactive effects and affect emotion.
This dissertation presents the results of two post-hoc analyses investigating the asso-
ciation of BNP and mental health in patients with coronary heart disease. The goal
was to assess the possible role of (NT-pro)BNP in mental health of depressed CHD
patients from the multicenter SPIRR-CAD trial. The hypothesis that BNP, like ANP,
shows anxiolytic-like effects was assessed using cross-sectional and longitudinal data.
Moreover, the scope of the cross-sectional analysis was broadened by additional mea-
sures of mental health, including quality of life, depression, vital exhaustion, coping
with illness, and type D personality. The general discussion will provide reflections
on the results in the context of current findings of the field, after which strengths and
limitations of the studies are summarized. Finally, implications for future research are
discussed, followed by the conclusion.
While natriuretic peptides are not known to be causally involved in heart disease,
they were shown to be powerful indicators of the severity of heart disease, prognostic
markers for CHD progression, and part of adaptive counter-regulation by reducing the
hemodynamic load of the heart (Bibbins-Domingo et al. 2007; Hodes and Lichtstein
2014). Our results extend these findings and show a role of NT-proBNP in various
measures of mental health. Such broader effect of natriuretic peptides has previously
been detected in patients during alcohol withdrawal (Koopmann et al. 2014), whereas
extensive studies in cardiac patients are missing. Although counterintuitive, our results
support the view of BNP as a general stress-buffering agent as part of adaptive counter-
regulation, even though NT-proBNP was also significantly associated with lower levels
of physical quality of life and more severe physical illness, which could expectedly im-
pair mental quality of life and emotional well-being. However, previous studies showed
that in cardiac patients, somatic measures of cardiac disease are, if at all, only weakly
associated with mental health (Jünger et al. 2002; Edelmann et al. 2011). Our results
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extend this finding to self-report measures of physical well-being and quality of life,
which do not seem to strongly affect the patients’ mental health.
An independent inverse association of NT-proBNP and anxiety has not been shown
before but was confirmed by a recent analysis of the multicenter Diagnostic Trial on
Prevalence and Clinical Course of Diastolic Dysfunction and Heart Failure (DIAST-
CHF) study, which revealed a significant negative association of NT-proBNP with
HADS anxiety in a sample of N = 1463 patients with cardiovascular risk factors (Sad-
lonova et al. 2019). Further results of the DIAST-CHF cohort showed significant
negative associations of anxiety with vasodilatory peptides, i.e. mid-regional proANP
(Meyer et al. 2015c; Sadlonova et al. 2019) and adrenomedullin (Meyer et al. 2015d),
as well as with the vasoconstrictive peptides arginine-vasopressin (Sadlonova et al.
2019) and endothelin (Meyer et al. 2015b). The various results of associations of va-
soactive peptides with emotion suggest a complex regulation system. Moreover, these
peptides influence the release of each other, acting as complex humoral feedback loops.
The tentative effects of BNP on anxiety and mental health could be mediated via cGMP
signaling pathways in the brain. When BNP binds to the natriuretic peptide receptor-
type A (NPR-A) the increased cGMP production can modulate synaptic activity in
various brain regions including the cerebellum, the amygdala, and the hippocampus.
Behavioral studies have indicated that cGMP signaling, and especially the dysfunc-
tion of cGMP signal transduction, is involved in anxiety, depression, addiction, and
schizophrenia (Kleppisch and Feil 2009). These long-term effects of cGMP could be
mediated via the regulation of gene expression in the respective brain areas. However,
these effects have only been shown for cGMP stimulated by nitric oxide and not yet
by natriuretic peptides (Kleppisch and Feil 2009).
6.1 Strengths and limitations
To date, this is the most extensive analysis of the association of NT-proBNP with
mental health measures in CHD patients. Internationally, few studies have described
the association of BNP and mental health in heart disease patients or other popula-
tions. In contrast to previous studies, the current data stem from a large sample of a
multicenter trial with a long follow-up period of 2 years. Moreover, the current study
not only assessed depression or anxiety, but a wider range of mental health measures
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and various somatic parameters.
Due to recruitment in German tertiary care centers, the majority of participants were
caucasian Germans and the sample mainly consisted of male participants. As the pri-
mary goal of the SPIRR-CAD trial was to test the effects of stepped psychotherapy on
symptoms of depression in CHD patients, the design did not primarily aim to assess
the association between and confirm directionality of NT-proBNP and mental health
measures. The cross-sectional analyses in publication 1 cannot show directionality of
the observed associations. However, the results indicate that BNP could have anx-
iolytic effects as predicted, and even broader effects on emotions. This is shown by
the fact that NT-proBNP not only correlated significantly with anxiety, but also with
various other measures of mental health. Although it seems plausible that BNP not
only protects against the adverse effects of anxiety, this conclusion cannot be drawn
from the presented results. In addition, the discovered sex-effect in the longitudinal
analysis needs replication. As the attrition rate was high, the sample of the longi-
tudinal analysis was small. Especially the number of women was rather low limiting
the generalizability of the results. The persisting high levels of anxiety in women with
very low levels of NT-proBNP has not been described before and should be studied
experimentally in more detail in the future. Naturally, women have higher levels of
BNP compared to men, however we did not find significant differences in NT-proBNP
between men and women in our sample (Redfield et al. 2002; Chang et al. 2007).
The proposed insufficient up-regulation of BNP in parts of the female sample could
have been influenced by menopause, which decreases the levels of BNP (Redfield et al.
2002; Glisic et al. 2018). However, as the majority of our female sample was post-
menopausal and the female sample was too small for a subgroup analysis, this remains
a hypothesis.
To test the primary outcomes of SPIRR-CAD, the inclusion criteria required mild to
moderate levels of depression (HADS-depression subscale > 7) and a large number of
patients additionally had elevated levels in other dimensions of distress. Moreover,
the sample showed significant differences in NT-proBNP levels between patients with
major depressive disorder versus without. Due to the pre-selection of the SPIRR-CAD
sample, we cannot assess a possible additional effect of depression or a moderating
effect of depression on the association of NT-proBNP and mental health. The longi-
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tudinal analysis of NT-proBNP and anxiety also entails a possible selection bias, as
described in publication 2.
6.2 Research implications
As discussed above, the design of SPIRR-CAD does not allow causal conclusions about
the role of NT-proBNP in emotion regulation. Future studies should test this rela-
tion experimentally as primary outcome and with a longitudinal design using multiple
measures of all tested variables. The apparent differing effects in male and female par-
ticipants should be investigated further. Therefore the design of future studies should
be balanced to include equal amounts of men and women and the sample size should
be powered to find subgroup effects. The vasodilatory effects of ANP and BNP have
led to the development of synthetic analogues (anaritide and nesiritide, respectively).
While they have been tested and approved as potential treatment of decompensated
heart failure, their effectiveness and safety have been questioned and their effect on
the patients’ mental health has yet to be assessed (Potter et al. 2006). While previous
studies and the present thesis have focused on ANP and BNP, the physical and mental
effects of C- and D-type natriuretic peptide (CNP and DNP, respectively), and urodi-
latin are poorly defined and need to be studied to understand the complex functions of
natriuretic peptides. Especially CNP could possibly be involved in emotion regulation,
as it had anxiogenic effects in studies in mice and healthy men (Montkowski et al.
1998; Kellner et al. 2003). The opposing effects on anxiety of ANP and BNP versus
CNP might explain why the sacubitril and valsartan containing medication Entresto R©
does not seem to affect the patients’ mental state. This could be expected as sacubitril
inhibits neprilysin, which slows down the degradation of natriuretic peptides and by
that increases their levels. It seems however that the levels of all natriuretic peptides
are increased and their anxiolytic and anxiogenic effects cancel each other out. CNP
is mainly expressed in the brain and was shown to be able to increase the permeability
of the blood-brain-barrier (Bohara et al. 2014). This could also influence the effect of
BNP in the brain, as it was found in the hypothalamus and the cerebral cortex, but
no BNP mRNA was observed in the brain (McKenzie et al. 1994; Langub et al. 1995;
Abdelalim et al. 2006).
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6.3 Final conclusion
Natriuretic peptides, as part of the neurobiological process in CHD, could modulate
the psychological adaptation of patients. CHD patients have an increased risk for de-
pression, anxiety and low quality of life, which have a negative effect on the progression
and prognosis of the heart disease. The observed negative associations of NT-proBNP
with anxiety support the notion that natriuretic peptides could play a crucial role in
counteracting this vicious circle. More surprisingly, the results showed negative asso-
ciations of NT-proBNP with a wider range of mental distress measures at baseline.
The longitudinal analysis revealed that women with very low levels of NT-proBNP at
baseline show persisting high levels of anxiety, which could be explained by insufficient
up-regulation of NT-proBNP despite CHD. Diagnosis and treatment of mental comor-
bidities are important, as they affect CHD. In conclusion, especially patients with an
insufficient up-regulation of NT-proBNP might be at risk for unfavorable outcomes and
inadequate adaptation.
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Figure 3: Consort flow chart.
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